Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC
Journal of Virology · 2024
DOI: 10.1128/jvi.00112-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Jack H Nunberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Montana Biotechnology Center, University of Montana, Missoula, Montana, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever, American, Junin virus, Viral Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Live-attenuated virus vaccines provide long-lived protection against viral disease but carry inherent risks of residual pathogenicity and genetic reversion. The live-attenuated Candid#1 vaccine was developed to protect Argentines against lethal infection by the Argentine hemorrhagic fever arenavirus, Junín virus. Despite its safety and efficacy in Phase III clinical study, the vaccine is not licensed in the US, in part due to concerns regarding the genetic stability of attenuation. Previous studies had identified a single F427I mutation in the transmembrane domain of the Candid#1 envelope glycoprotein GPC as the key determinant of attenuation, as well as the propensity of this mutation to revert upon passage in cell culture and neonatal mice. To ascertain the consequences of this reversion event, we introduced the I427F mutation into recombinant Candid#1 (I427F rCan) and investigated the effects in two validated small-animal models: in mice expressing the essential virus receptor (human transferrin receptor 1; huTfR1) and in the conventional guinea pig model. We report that I427F rCan displays only modest virulence in huTfR1 mice and appears attenuated in guinea pigs. Reversion at another attenuating locus in Candid#1 GPC (T168A) was also examined, and a similar pattern was observed. By contrast, virus bearing both revertant mutations (A168T+I427F rCan) approached the lethal virulence of the pathogenic Romero strain in huTfR1 mice. Virulence was less extreme in guinea pigs. Our findings suggest that genetic stabilization at both positions is required to minimize the likelihood of reversion to virulence in a second-generation Candid#1 vaccine. IMPORTANCE Live-attenuated virus vaccines, such as measles/mumps/rubella and oral poliovirus, provide robust protection against disease but carry with them the risk of genetic reversion to the virulent form. Here, we analyze the genetics of reversion in the live-attenuated Candid#1 vaccine that is used to protect against Argentine hemorrhagic fever, an often-lethal disease caused by the Junín arenavirus. In two validated small-animal models, we find that restoration of virulence in recombinant Candid#1 viruses requires back-mutation at two positions specific to the Candid#1 envelope glycoprotein GPC, at positions 168 and 427. Viruses bearing only a single change showed only modest virulence. We discuss strategies to genetically harden Candid#1 GPC against these two reversion events in order to develop a safer second-generation Candid#1 vaccine virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montana Biotechnology Center, University of Montana, Missoula, Montana, USA.
- Department of Animal Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.
- Institute for Antiviral Research, Utah State University, Logan, Utah, USA.
- Department of Plants, Soils, and Climate, Utah State University, Logan, Utah, USA.
- Center for Integrated BioSystems, Utah State University, Logan, Utah, USA.
ORCID-Profile: Jack H Nunberg, Brian B Gowen
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Nunberg, J. H., Westover, J. B., York, J., Jung, K. H., Bailey, K. W., Boardman, K. M., Li, M., Furnell, R. S., Wasson, S. R., Murray, J. S., Kaundal, R., Thomas, A. J., & Gowen, B. B. (2024). Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC. Journal of Virology. https://doi.org/10.1128/jvi.00112-24
Vancouver
Nunberg JH, Westover JB, York J, Jung KH, Bailey KW, Boardman KM, et al. Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC. Journal of Virology. 2024. doi:10.1128/jvi.00112-24
BibTeX
@article{Nunberg2024,
author = {Nunberg, Jack H and Westover, Jonna B and York, Joanne and Jung, Kie Hoon and Bailey, Kevin W and Boardman, Kirsten M and Li, Minghao and Furnell, Rachel S and Wasson, Samantha R and Murray, Justin S and Kaundal, Rakesh and Thomas, Aaron J and Gowen, Brian B},
title = {Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.00112-24}
}
EUVIMED